Rare lung & airway condition
Alpha-1 antitrypsin deficiency lung disease
Alpha-1 antitrypsin deficiency is a genetic shortfall in the lung's main protective protein, causing early-onset emphysema - especially in smokers - and every COPD patient should be tested once.
Key points
The essentials at a glance.
What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.
-
01
Guidelines recommend testing everyone with COPD at least once with a simple blood test.
-
02
Suspicion should be higher with emphysema under 50, basal-predominant emphysema, or a family history.
-
03
Severe deficiency (typically ZZ genotype) plus smoking is a devastating combination - never smoking, or stopping, transforms prognosis.
-
04
The liver can also be affected and merits baseline assessment.
-
05
Management is rigorous COPD care, vaccination and rehabilitation; intravenous augmentation therapy exists but is not routinely commissioned on the NHS - specialist centres advise, and family screening is offered.
Understanding it
What it is, and what happens next.
In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.
Alpha-1 antitrypsin shields the delicate walls of the air sacs from the enzymes of inflammation; those born with severe deficiency lose that shield, and cigarette smoke both disables what little protein exists and summons the very enzymes it should restrain. Emphysema arrives decades early, characteristically at the lung bases, and the diagnosis is missed simply because no one sends the test.
A confirmed deficiency reshapes care: absolute priority on smoking abstinence and occupational dust avoidance, optimised inhaled therapy and pulmonary rehabilitation, liver surveillance, genetic counselling with testing of siblings and children, and referral to a specialist alpha-1 service for discussion of augmentation therapy, research trials and transplant timing where disease is advanced. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.
A quiet reminder
This guide is for information, not medical advice.
Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.
Published 2026-09-27 · Next review 2027-09-27
Frequently asked
Common questions about Alpha-1 antitrypsin deficiency lung disease.
Quick, plain-English answers to what people ask us most.
-
What is alpha-1 antitrypsin deficiency lung disease?
This refers to early-onset emphysema caused by low levels of alpha-1 antitrypsin, a protein that normally protects lung tissue from damage, leaving the lungs vulnerable to breakdown, especially in smokers.
-
What causes alpha-1 antitrypsin lung disease?
It is caused by inherited gene variants that result in low blood levels of alpha-1 antitrypsin, meaning the lungs lack sufficient protection against enzymes that break down lung tissue, particularly during inflammation from smoking or infection.
-
What are the symptoms of alpha-1 antitrypsin lung disease?
Symptoms include breathlessness, wheeze, and a persistent cough, often developing at a notably younger age (30s to 40s) than typical smoking-related emphysema.
-
Is alpha-1 antitrypsin lung disease dangerous?
Yes, it can cause severe, early emphysema and significant breathing impairment, particularly in smokers, though never smoking substantially reduces this risk.
-
Can alpha-1 antitrypsin lung disease be treated?
Yes, strict smoking avoidance is essential, and eligible patients with significant deficiency and lung disease may benefit from augmentation therapy, which replaces the missing protein intravenously.
-
How is alpha-1 antitrypsin lung disease treated?
Treatment includes standard respiratory therapies such as bronchodilators and pulmonary rehabilitation, strict smoking cessation, and intravenous augmentation therapy for eligible patients to slow lung function decline.
-
How is alpha-1 antitrypsin lung disease monitored?
Monitoring typically includes regular lung function tests (spirometry) and imaging to track disease progression and guide treatment decisions over time.
-
Alpha-1 antitrypsin lung disease vs typical smoking-related COPD — what's the difference?
Typical COPD develops gradually over decades of smoking, usually appearing in older age, while alpha-1 antitrypsin lung disease causes emphysema to develop much earlier in life due to an underlying genetic protein deficiency, even in some non-smokers.
-
Does augmentation therapy cure alpha-1 antitrypsin lung disease?
No, it does not cure the condition but can help slow the progression of lung damage in eligible patients by replacing the missing protective protein, alongside other standard respiratory care.
-
When should I see a doctor about possible alpha-1 antitrypsin lung disease, and how quickly can I be seen privately?
See a doctor if you have early, unexplained breathlessness or emphysema, especially before age 45 or as a non-smoker. NHS respiratory referral can take 20 to 45 or more weeks, while private specialist assessment is often available within about two weeks.